NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer
- 1 June 2017
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 145 (3) , 420-425
Abstract
No abstract availableKeywords
Funding Information
- Cancer Research Institute (T32CA108456)
- Ludwig Institute for Cancer Research (1K01LM012100)
- Cancer Research Institute (1R01CA158318-01A1)
- Ovarian Cancer Research Fund (P50CA159981-01A1)
- National Cancer Institute (P30CA016056)
- NIH (P01CA190174)
This publication has 29 references indexed in Scilit:
- Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian CancerJournal of Clinical Oncology, 2015
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancerScience, 2015
- Adaptive immunity maintains occult cancer in an equilibrium stateNature, 2007
- Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancerProceedings of the National Academy of Sciences, 2007
- Influence of CD4+CD25+ Regulatory T Cells on Low/High-Avidity CD4+ T Cells following Peptide VaccinationThe Journal of Immunology, 2006
- Intraperitoneal Cisplatin and Paclitaxel in Ovarian CancerNew England Journal of Medicine, 2006
- NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer.2003
- Ny-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumor grade.2001
- Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage III Ovarian CancerNew England Journal of Medicine, 1996
- Identification of the MAGE-1 gene product by monoclonal and polyclonal antibodies.Proceedings of the National Academy of Sciences, 1994